June 6, 2017
FDA OK’s Alkermes’s schizophrenia drug
The U.S. Food and Drug Administration (FDA) has approved Alkermes’s two-month Aristada (aripiprazole lauroxil) extended-release injectable suspension for the treatment of schizophrenia.